Lallemand, GM Pharmaceuticals launch Ismigen in Georgia

16th November 2011 (Last Updated November 16th, 2011 18:30)

Lallemand Pharma and GM Pharmaceuticals have introduced new oral vaccine Ismigen in Georgia, US, to prevent acute exacerbations in chronic obstructive pulmonary disease.

Lallemand Pharma and GM Pharmaceuticals have introduced new oral vaccine Ismigen in Georgia, US, to prevent acute exacerbations in chronic obstructive pulmonary disease.

Ismigen, a polyvalent mechanical bacterial lysate, is also used to prevent acute, sub-acute, recurrent or chronic infections of the upper and lower airways and the bronchopulmonary tree.

The drug is prepared from a large array of inactivated pathogenic bacteria via mechanical lysis.

Switzerland-based Lallemand Pharma's key products are comprised of immunostimulant drugs Ismigen, Immubron and Respibron, which target infections of the respiratory tract.